Searching journal content for anti-CTLA-4 (as phrase) in full text.

Displaying results 1-7 of 7
For checked items
  1. Thematic Review:
    • Robert C Mould,
    • Jacob P van Vloten,
    • Amanda W K AuYeung,
    • Khalil Karimi,
    • and Byram W Bridle
    Immune responses in the thyroid cancer microenvironment: making immunotherapy a possible mission Endocr Relat Cancer 24 (12) T311-T329, doi:10.1530/ERC-17-0316 first published on 14 September 2017
    ...of thyroid cancers. Notably, anaplastic thyroid cancers, for which there is the greatest need for new treatments, may be most amenable to PD-L1 blockade. CTLA-4 blockade therapy is poorly studied in the context of thyroid cancers. However, anti-CTLA-4 and anti-PD-1 are currently being tested in several ~~~
  2. Thematic Review:
    • Priscilla Cukier,
    • Fernando C Santini,
    • Mariana Scaranti,
    • and Ana O Hoff
    Endocrine side effects of cancer immunotherapy Endocr Relat Cancer 24 (12) T331-T347, doi:10.1530/ERC-17-0358 first published on 12 October 2017
    ...(Table1). Of note, combination of anti-CTLA4 and anti-PD-1 is approved for cutaneous melanoma, and promising results from early phase trials have been published for other malignancies (Antonia etal. 2016, Hellmann etal. 2017). Given that immune-inhibitory pathways have an important role ~~~
  3. Thematic Review:
    • Lucas Leite Cunha,
    • Marjory Alana Marcello,
    • Vinicius Rocha-Santos,
    • and Laura Sterian Ward
    Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way Endocr Relat Cancer 24 (12) T261-T281, doi:10.1530/ERC-17-0222 first published on 11 September 2017
    ...-cell activation (Fig.1) (Pardoll 2012, Ribas 2012). Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and anti-CTLA-4 antibody T-cell recognition of antigen through the T-cell receptor (TCR) is regulated by a balance between costimulatory and inhibitory signals T-cell recognition of antigen through the TCR ~~~
  4. Thematic Review:
    • Melissa Gamat and
    • Douglas G McNeel
    Androgen deprivation and immunotherapy for the treatment of prostate cancer Endocr Relat Cancer 24 (12) T297-T310, doi:10.1530/ERC-17-0145 first published on 16 August 2017
    ...-expressing tumor cells as mechanisms of resistance to ADT (Pending, trial ongoing) NCT02411786 T-cell checkpoint inhibitor: Tremelimumab Bicalutamide Phase I Patients with non-castrate PSArecurrent prostate cancer received two 28-day courses of bicalutamide 3 months apart, with anti-CTLA-4 delivered at end of each ~~~
  5. Review:
    • S Latteyer,
    • V Tiedje,
    • B Schilling,
    • and D Führer
    Perspectives for immunotherapy in endocrine cancer Endocr Relat Cancer 23 (10) R469-R484, doi:10.1530/ERC-16-0169 first published on 2 August 2016
    [email protected] Key Words f immunooncology f immune checkpoint blockade f anti-CTLA-4 f anti-PD-1 f tumor microenvironment f endocrine and neuroendocrine cancer R470Review S Latteyer etal. Immunotherapy in endocrine cancer DOI: 10.1530/ERC-16-0169 http://.endocrinology-journals.org 2016 Society for Endocrinology ~~~
  6. Research:
    • Shahnawaz Imam,
    • Rodis Paparodis,
    • Deepak Sharma,
    • and Juan Carlos Jaume
    Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity Endocr Relat Cancer 21 (3) 505-516, doi:10.1530/ERC-13-0436 first published on 12 March 2014
    ..., equilibrium, and escape) which help to explain our observations and give us a mechanistic framework for our hypothesis. Lymphocytes in Hashimotos are clearly capable of elimination of the target. As with anti-CTLA-4 immunotherapy, exacerbation of rampant autoimmunity may help to eliminate cancer (Mellman et ~~~
  7. Research:
    • Mabel Ryder,
    • Margaret Callahan,
    • Michael A Postow,
    • Jedd Wolchok,
    • and James A Fagin
    Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution Endocr Relat Cancer 21 (2) 371-381, doi:10.1530/ERC-13-0499
    ...antiCTLA4 therapy, this was a rare disease confined primarily to postpartum women (Caturegli et al. 2005). Although the US FDA approval of ipilimumab stipulates that thyroidstimulating hormone (TSH) levels be evaluated before administration of each dose of ipilimumab as a screen for thyroid dysfunction ~~~
For checked items

Search Results

New Search

Modify Results

Citation format:
Results / page:
Results order:

This search

  • Alert me when new articles matching this search are published
  • Download all citations on this page to my citation manager

New Articles: issue in progress

  1. December 2017, 24 (12)
  1. Current Issue
  1. Alert me to new issues of Endocrine-Related Cancer

Most